Expression of MUC1 in different tumours and its clinical significance (Review)

Lan, Yue; Ni, Weihua; Tai, Guihua

doi:10.3892/mco.2022.2594

Cited by 16 publications

(7 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mucins are a family of high-molecular-weight glycoproteins. Among them, transmembrane protein mucin-1 (MUC1) is widely studied for its role in several kinds of cancers [ 1 ]. Usually, epithelial cells’ surfaces are covered in MUC1, which creates a dense mesh that protects cells from harsh external circumstances, forming a protective barrier across the mucosal surface [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of MUC1 in Renal Cell Carcinoma

Milella,

Rutigliano,

Lasorsa

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Mucins are a family of high-molecular-weight glycoproteins. MUC1 is widely studied for its role in distinct types of cancers. In many human epithelial malignancies, MUC1 is frequently overexpressed, and its intracellular activities are crucial for cell biology. MUC1 overexpression can enhance cancer cell proliferation by modulating cell metabolism. When epithelial cells lose their tight connections, due to the loss of polarity, the mucins become dispersed on both sides of the epithelial membrane, leading to an abnormal mucin interactome with the membrane. Tumor-related MUC1 exhibits certain features, such as loss of apical localization and aberrant glycosylation that might cause the formation of tumor-related antigen epitopes. Renal cell carcinoma (RCC) accounts for approximately 3% of adult malignancies and it is the most common kidney cancer. The exact role of MUC1 in this tumor is unknown. Evidence suggests that it may play a role in several oncogenic pathways, including proliferation, metabolic reprogramming, chemoresistance, and angiogenesis. The purpose of this review is to explore the role of MUC1 and the meaning of its overexpression in epithelial tumors and in particular in RCC.

show abstract

Section: Introductionmentioning

confidence: 99%

The Role of MUC1 in Renal Cell Carcinoma

Milella,

Rutigliano,

Lasorsa

et al. 2024

Biomolecules

View full text Add to dashboard Cite

show abstract

“…This study indicates high expression level of MUC1 in normal pancreas which is almost 50 times higher than the MUC13 expression. MUC1 is one of the oncogene in PanCa [25] and other cancers [7] , thus MUC1 holds the gold standard cancer biomarker status. Therefore, MUC1 was used as reference gene for the correlation analysis with MUC13.…”

Section: Discussionmentioning

confidence: 99%

“…Among all mucins, MUC1 is recognized as reference gene in gastro-intestinal cancers and its unusual upregulation is observed in more than 60% of PanCa incidents, which corelates with the poor prognosis of the patients. It has been observed that MUC1 upregulation is also linked to the progression of different types of cancer, such as ovarian, lung, liver, cholangiocarcinoma, gallbladder, thyroid, colorectal, pancreatic and breast cancer [7] .…”

Section: Introductionmentioning

confidence: 99%

Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer

Dhasmana

Agarwal

et al. 2023

Computational and Structural Biotechnology Journal

View full text Add to dashboard Cite

“…Thus, transmembrane mucins are well-recognized for their role in cancer initiation, progression, metastasis, and immune evasion [12][13][14]16]. The abnormal expression of transmembrane mucins is one of the primary features of adenocarcinomas, which include colon, breast, pancreatic, lung, and ovarian cancer [20,36]. More than 90% of triple-negative breast cancers (TNBC) and 80% of pancreatic ductal adenocarcinoma (PDAC), both highly aggressive cancer types, present with the aberrantly expressed MUC1 [37,38].…”

Section: Muc1 Proteinmentioning

confidence: 99%

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

Ayyalasomayajula,

Cudic

2024

Cancers

View full text Add to dashboard Cite

Siglecs play a key role in mediating cell–cell interactions via the recognition of different sialylated glycoconjugates, including tumor-associated MUC1, which can lead to the activation or inhibition of the immune response. The activation occurs through the signaling of Siglecs with the cytoplasmic immunoreceptor tyrosine-based activation motif (ITAM)-containing proteins, while the inhibition signal is a result of the interaction of intracellular immunoreceptor tyrosine-based inhibition motif (ITIM)-bearing receptors. The interaction of tumor-associated MUC1 sialylated glycans with Siglecs via ITIM motifs decreases antitumor immunity. Consequently, these interactions are expected to play a key role in tumor evasion. Efforts to modulate the response of immune cells by blocking the immune-suppressive effects of inhibitory Siglecs, driving immune-activating Siglecs, and/or altering the synthesis and expression of the sialic acid glycocalyx are new therapeutic strategies deserving further investigation. We will highlight the role of Siglec’s family receptors in immune evasion through interactions with glycan ligands in their natural context, presented on the protein such as MUC1, factors affecting their fine binding specificities, such as the role of multivalency either at the ligand or receptor side, their spatial organization, and finally the current and future therapeutic interventions targeting the Siglec–sialylated MUC1 immune axis in cancer.

show abstract

Expression of MUC1 in different tumours and its clinical significance (Review)

Cited by 16 publications

References 95 publications

The Role of MUC1 in Renal Cell Carcinoma

The Role of MUC1 in Renal Cell Carcinoma

Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer

Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer

Contact Info

Product

Resources

About